ArticleHepatology international2023

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.

Te-Sheng Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.